Semaglutide Is a Dated Asset: Reading Novo's Patent Cliff as an Unlock Calendar

The clock on Novo Nordisk's most valuable asset is printed on a public calendar, and Morgan Stanley just priced Nova as if a reasonable person can now read it. Step one is opening that calendar. The exit is written before any entry.

The calendar semaglutide runs on

The downgrade landed on September 11, 2026, one item before the company's September 21 capital-markets day: Morgan Stanley cut Novo to Underweight from Equal-weight, and shares dipped about 2.6% in early Copenhagen trade. The stated reason is a phrase that sounds like boilerplate but carries the whole argument — a "patent cliff" on semaglutide, the molecule inside both Ozempic and Wegovy.

A patent cliff is exactly what a crypto trader would call an unlock schedule. The revenue from a drug is not a perpetual claim; it is a dated stream backed by exclusivity, and exclusivity expires on named days. Novo is more exposed to this clock than almost any company its size, because semaglutide accounts for roughly 75% of its 2026 sales. Whatever is true today about demand, the question that now prices the stock is what that revenue is worth after each market's lock starts to fail.

Here is that calendar, from the disclosed schedules:

Market	First loss of exclusivity
India, China, Brazil	patents expire March 2026
Canada	2026
Europe, Japan	2031
United States	2032

Those 2026 markets alone are home to about 40% of the world's population and roughly a third of the world's adults with obesity. Generic entrants in price-sensitive markets can slash prices dramatically — estimates have run as high as 80% off. At least 13 companies have already signaled to the FDA that they want into semaglutide, and a wave of Indian and Chinese candidates is in late-stage trials. The calendar tells you the mechanism; the generic queue tells you it is being acted on.

What already got priced

Now the valuation math that makes this more than a headline. Novo trades at about 12.5x estimated 2027 earnings.That is a 7% discount to large European pharma peers, yet a 35% premium to global companies that already face their own loss of exclusivity — Sanofi at 8x, GSK at 10x. Morgan Stanley's models show semaglutide still supplying about 59% of Novo's sales in 2031, the year its European lock begins. In other words, a decade out, this company still leans on a molecule going generic, and the market is being asked to pay a premium for a name that has not yet earned the discount the clock implies.

The near term does not soften the read. Novo has twice raised its 2026 guidance this year, and it now points to 0% to -6% constant-currency adjusted sales growth — still the first annual sales decline since 2017. Underneath the headline, the quality is thin: U.S. injectable Wegovy sales fell about 22% at constant currency in the second quarter even as prescription counts rose, because patients were shifting to lower-priced self-pay. The offsets the company points to have their own clocks. The oral Wegovy pill owns roughly 90% of the U.S. oral obesity market after a fast launch, but weekly new-script growth is decelerating and only about 30% of scripts land at the higher-dose, higher-priced tiers. Even a franchise Morgan Stanley sizes at $10 billion by 2031, the analysts wrote, "will not be enough to offset pricing and competitive headwinds."

That last line is the two readings, put side by side, and the data that separates them. Bull reading: the U.S. — the biggest and highest-priced market — is safe until 2032, which is the entire game for the next five years, and the discount to European pharma is the entry. Bear reading: a terminal value on a dated revenue stream is precisely what should be discounted, and Novo is still priced as a compounding grower rather than a company whose engine loses its lock. The separator is not a story; it is the dated events below.

Five dated events, and the one that retires the playbook

This is a trade you can place without predicting anything, because the inputs are scheduled. Here is the checklist, with the screen open tonight:

• September 21, 2026 — capital-markets day. Watch whether management shows a credible path off semaglutide's clock, or reiterates the oral vision. Morgan Stanley sees limited scope for major announcements.
• October 1, 2026 —CVS Caremark opens its formulary to competitors. A real, dated share-loss event in Novo's most important market.
• January 2027 — the agreed 50% U.S. list-price cut on Wegovy and Ozempic, to about $675, takes effect.
• Through 2026 — India, China, and Brazil generics actually launch; watch the realized discount, not the modeled one.
• 2027 —Eli Lilly submits retatrutide, closing the oral gap Novo now leads.

The obsolescence clause — the regime change that retires this playbook — is equally precise. The "pay for a dying but dated revenue stream" read stops working when either of two things happens: the next molecule reliably carries more than half of Novo's revenue before 2031 (which would re-date the calendar), or Novo's multiple compresses down to the 8x–10x band the LOE peers already trade at (which would mean the discount is done and you are simply late). Re-verify at each dated event; the calendar, not conviction, decides.

Novo is down about 75% from its mid-2024 peak above 1,000 Danish crowns. A fallen hero is a siren, not a signal. The discipline here is not predicting when generics land — the schedule tells you, and it starts this month. It is refusing to pay twice: once for the narrative that made the stock a world-beater, and again for a terminal value the clock has already begun winding down.